After validating inducible NAP expression (Supplementary Fig. 1), we evaluated the efficacy of CAR(NAP) T cells to target endogenously expressed murine CD19 and disialoganglioside (GD2) in two immunocompetent, syngeneic mouse models of cancer, A20 (lymphoma) and NXS2 (neuroblastoma) (Fig. 1b,c). This evidence concerns the gene CD19 and lymphoma.